Velan (VLN) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
12 Oct, 2025Executive summary
Q2 FY2026 sales were $67.6 million, down 13% year-over-year, with adjusted EBITDA of $3.4 million and operating income of $0.4 million, impacted by $12 million in rescheduled deliveries and tariff-related delays.
Backlog increased 4% since the start of the year to $285.8 million, with 88.3% deliverable within 12 months.
Significant progress in nuclear and clean energy sectors, including a $15 million Ontario reactor valve contract and first SMR deployment at Darlington.
First order delivered from new Saudi Arabia plant, supporting expansion in the Middle East oilfield valve market.
Major transactions included the sale of French subsidiaries and settlement of asbestos-related liabilities, strengthening the balance sheet.
Financial highlights
Q2 sales declined 13% year-over-year to $67.6 million; excluding a $5.2 million non-recurring item last year, the decrease was 6.7%.
Gross profit for Q2 was $15.7 million (23.2% margin), down from $20 million (25.7%) last year, mainly due to lower volume, less favorable mix, and tariffs.
Adjusted EBITDA was $3.4 million, down from $6.7 million last year; adjusted net loss was $1.2 million, compared to adjusted net income of $2.8 million a year ago.
Six-month sales were $139.8 million, up 0.9% year-over-year; gross profit was $36.3 million (26.0% margin).
Cash used in operations was $16 million, compared to $4.7 million generated last year, due to lower profitability and higher working capital needs.
Outlook and guidance
Backlog and order intake remain strong, with significant contracts in nuclear, defense, and oil & gas expected to drive future growth.
88.3% of the $285.8 million backlog is expected to be delivered within 12 months.
Management confident in sustaining backlog growth and capitalizing on nuclear and clean energy opportunities.
Tariff and supply chain disruptions expected to be managed through customer negotiations and pricing adjustments.
Strong liquidity position with $96 million available for expansion and investment.
Latest events from Velan
- Bookings and backlog improved, supporting growth and cash flow focus for 2025.VLN
AGM 20243 Feb 2026 - Q1 sales up 14.5%, gross margin 30.7%, backlog $528.3M, and major nuclear deal signed.VLN
Q1 20253 Feb 2026 - Bookings and sales soared, backlog reached $548.1M, and net income turned positive.VLN
Q2 202519 Jan 2026 - Strong backlog, major asset sale, and ownership transition marked Q3 2026.VLN
Q3 202615 Jan 2026 - Q3 saw 18.1% sales growth, margin gains, and risk reduction from major divestitures.VLN
Q3 202510 Jan 2026 - Shareholders approved the $201.1 million sale of French subsidiaries to Framatome.VLN
EGM 202526 Dec 2025 - Sales and margins surged, with divestitures and a special dividend boosting future prospects.VLN
Q4 202524 Nov 2025 - 18.6% sales growth, margin gains, and record cash drive a higher dividend and strong outlook.VLN
Q1 202616 Nov 2025 - Strong growth, risk reduction, and strategic expansion defined the year, with all motions approved.VLN
AGM 202516 Nov 2025